Loxo Oncology Inc to Present LOXO-101 Phase 1 Larotrectinib Data Presented at 2017 ASCO

4/6/2017 18:30

Conference Call Loxo Oncology Inc

Loxo Oncology Inc Conference call or earnings call will be held on Jun 4, 2017
During the earnings conference call’s session, Loxo Oncology Inc will provide updated information and financial performance report status.
In order to join the earning call, dial the conference’s bridge and key in the PIN code. Contact Loxo Oncology Inc for this information
More and more companies choose to conduct their earnings calls through conference calls and online meetings and it’s important to keep up to date with all relevant information.
Need a conference calls service solution? Try QCONF conferencing today, Sign up now and get 5 free conference calls (no credit card required)
Is this is your first earnings call? Check out Nasdaq guide for how to read an earnings report?
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. As genetic testing in cancer becomes more routine, we are learning that cancers arising in diverse sites in the body may share the same type of genetic alterations.    
Read more Conference Call

Loxo Oncology Inc (LOXO)

1281 Tresser Boulevard, Stamford Connecticut 06901, United States